The leading players in the Nasal Drug Delivery Technology Market include Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Pfizer, Inc. (U.S.), AstraZeneca plc. (U.S.), AptarGroup (U.S.), and GlaxoSmithKline plc (U.K.).
Companies are focused on various organic strategies such as product launches to strengthen their position in the market.
This research study involved the use of extensive secondary sources; directories; databases such as Hoover’s, Bloomberg Business, Factiva, and Avention; white papers; annual reports; company house documents; and SEC filings of companies.
For estimating the size of the Nasal Drug Delivery Technology Market, the segmental market revenues were obtained from secondary sources through extensive primary interviews. The segment-level markets were then added up to reach the total market size of each segment (dosage form, therapeutic application, end user, system, container, and region). The Nasal Drug Delivery Technology Market size was derived by adding the markets of all these segments. The total market derived through the bottom-up approach was again validated through secondary sources and interviews.
Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=192818058
The overall market size derived by the bottom-up approach was used in the top-down procedure to estimate the size of the nasal drug delivery technology through the percentage splits obtained from secondary and primary research for each product segment.
Product launches and approvals accounted for the largest share of the total strategic developments in the Nasal Drug Delivery Technology Market from January 2014 to November 2016. The major players that adopted these strategies include Johnson & Johnson (U.S.), GlaxoSmithKline plc (U.K.), and Novartis AG (Switzerland).
In February 2016, Johnson & Johnson launched the RHINOCORT allergy spray. This spray is used for the treatment of nasal congestion and itchy & runny nose. This launch helped the company expand its product portfolio in the market. Further, in June 2014, GSK received the FDA Approval for Flonase Allergy Relief (fluticasone propionate 50 mcg spray). This nasal spray is used for the treatment of hay fever or upper respiratory allergies.
Related Reports:
Nasal Drug Delivery Technology Market by Dosage Form (Nasal Drops, Sprays, Powder, Gel), System (Multidose, Unit Dose, BI-Dose), Therapeutic Applications (Rhinitis, Congestion, Vaccinations), End User (Hospitals, Homecare) – Global Forecast to 2021
The global nasal drug delivery technology market is projected to reach USD 64.20 Billion by 2021 from USD 44.00 Billion in 2016, at a CAGR of 6.5% during the forecast period. This market is segmented based on dosage form, therapeutic application, end user, system, container, and region.
